Respiratory syncytial virus prophylaxis: Cost-effective analysis in Argentina

Pediatric Infectious Disease Journal

Volumn 21, Issue 4, 2002, Pages 287-291

  Fariña, Diana ^a   Rodríguez, Susana P ^a   Bauer, Gabriela ^a   Novali, Luis ^a   Bouzas, Liliana ^a   González, Helena ^a   Gilli, Clara ^a   Laffaire, Enrique ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cost effective analysis; Low socioeconomic status; Palivizumab; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARGENTINA; ARTICLE; BRONCHIOLITIS; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFANT; LUNG DYSPLASIA; MALE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; ARGENTINA; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0036226136     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200204000-00006     Document Type: Article

References (21)

1. Respiratory syncytial virus: A continuing culprit and conundrum
2. Prevention strategies for respiratory syncytial virus: Passive and active immunization
3. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection
4. Community and hospital-acquired respiratory syncytial virus infection in Chile
5. RSV Infection in developed and developing countries
6. Respiratory syncytial virus infections in hospitalized Canadian infants: Regional differences inpatient populations and management practices
7. Hospitalization of Jewish and Bedouin infants in Southern Israel for bronchiolitis caused by respiratory syncytial virus
8. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level
9. Respiratory syncytial virus infection
10. The epidemiology of acute respiratory tract infection in young infants: Comparison of findings from several developing countries
11. Respiratory course and predictive factors for respiratory morbidity in infants who had bronchopulmonary dysplasia
12. Palivizumab: A humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants
13. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on use of RSV-IGIV
14. Expanded access study with palivizumab in 1999: Southern hemisphere [C2]
15. Questions about palivizumab
16. Costeffectiveness of respiratory syncytial virus prophylaxis among preterm infants
17. Respiratory syncytial virus and premature infants born at 32 weeks gestation or earlier
18. Cost and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants
19. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: Reduction in incidence, severity of illness and cost
20. Hospitalization for RSV infection in ex-preterm infants: Implication for use of RSV immunoglobulin